Fulcrum Stock Crashes After Scrapping Sickle Cell Drug Over FDA Cancer Fears
Fulcrum stock dropped after canceling its sickle cell drug over cancer risk concerns; may sell company, $333M cash.
/ 6 items
#FULC↓
Agios Moves Closer to Fast FDA Approval for New Sickle Cell Pill
Agios is pursuing accelerated FDA approval for mitapivat, a new oral pill for sickle cell disease. The RISE UP trial showed better hemoglobin levels, fewer pain crises, and good safety.
Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.
Higher Dose Sickle Cell Pill Shows Improved Results, But Experts Urge Caution
Fulcrum's (FULC) experimental oral treatment for sickle cell disease demonstrates stronger fetal hemoglobin increases at 20mg dose, though researchers emphasize it's not a cure for the genetic disorder.
Key Pharma Stock Updates: Merck, BeOne, MeiraGTx, MannKind, and Fulcrum
Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets.
Fulcrum Gains Momentum After Agios Trial Miss
Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.